Article Text
Summary
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.
- Cardiovascular system
- Safety
- Unwanted effects / adverse reactions
Statistics from Altmetric.com
Footnotes
Contributors MJ and SB were responsible for the manuscript preparation, writing and data collection. KB and LC were responsible for the revision and critique review of the article.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.